GlassScriptPhysician profile
Justin R Chen
NPI 1962728642
$23,876.10
in general payments reported to CMS, 2019-2025
35 companies · $6,730 in 2025
The $6,730 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $1,291 · 2021: $2,110 · 2022: $2,514 · 2023: $6,631 · 2024: $3,007 · 2025: $6,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,359 · Consulting Fee: $7,426 · Travel and Lodging: $375 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,358.65 |
| Consulting Fee | $7,425.75 |
| Travel and Lodging | $375.27 |
| Education | $208.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,500.18 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $4,330.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,863.03 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,638.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $1,302.39 | 2019-2025 | |
| Genentech USA, INC. | $1,286.51 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $801.79 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Sanofi-Aventis U.S. LLC | $301.64 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $301.05 | 2023-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $269.55 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $254.65 | 2022-2025 | Dupixent |
| Pfizer INC. | $235.00 | 2020-2025 | |
| Csl Behring | $223.46 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.64 | 2019-2021 | |
| Kaleo, INC. | $182.32 | 2020-2023 | Auvi-Q |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $147.12 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $139.68 | 2022-2024 | |
| Amgen INC. | $110.54 | 2022-2025 | Tezspire |
| Hikma Pharmaceuticals USA | $108.11 | 2023-2025 | Ryaltris |
| Optinose US, INC. | $102.15 | 2019 | |
| Pharming Healthcare, INC. | $67.55 | 2023-2024 | Ruconest |
| Hospira, INC. | $66.04 | 2024-2025 | |
| Incyte Corporation | $56.81 | 2022-2025 | Opzelura |
| Genentech, INC. | $47.95 | 2020 | |
| Alk-Abello, INC | $47.34 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $45.97 | 2025 | Neffy |
| Octapharma USA, INC. | $42.86 | 2021 | |
| Stryker Corporation | $39.70 | 2025 | Clarifix |
| Lilly USA, LLC | $33.30 | 2024-2025 | Ebglyss |
| Kowa Pharmaceuticals America, INC. | $31.76 | 2025 | Zoryve |
| Uswm, LLC | $30.00 | 2021 | |
| Aimmune Therapeutics, INC. | $25.63 | 2020-2022 | |
| Blueprint Medicines Corporation | $23.00 | 2023 | Ayvakit |
| Galderma Laboratories, L.P. | $15.27 | 2025 | Nemluvio |
| Leo Pharma INC. | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.